ATRCMEDIUM SIGNALOPERATIONAL10-K

ATRC expanded its business description to include amputation surgeries and highlighted upgraded clinical guidelines while showing meaningful improvement in profitability metrics.

The company is broadening its addressable market beyond traditional cardiac procedures to include amputation surgeries, potentially expanding revenue opportunities. The reference to upgraded American medical society guidelines (Class 1 recommendation for LAAM and Class 2 for Hybrid AF Therapy) suggests stronger clinical validation that could drive adoption.

Comparing 2026-02-19 vs 2025-02-14View on EDGAR →
FINANCIAL ANALYSIS

ATRC showed solid operational improvement with 15.4% revenue growth to $201.6M and comparable gross profit expansion. Operating losses and net losses were substantially reduced, indicating meaningful progress toward profitability. The company strengthened its balance sheet with cash growing to $167.4M while maintaining controlled capital expenditures at $9.1M, suggesting disciplined investment alongside growth.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+76.4%
-$40.0M→-$9.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+74.4%
-$44.7M→-$11.4M

Net income grew 74.4% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+38.9%
$5.0M→$6.9M

Interest expense surged 38.9% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+36.4%
$122.7M→$167.4M

Cash position surged 36.4% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-21%
$11.5M→$9.1M

Capex reduced 21% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+20.4%
$267.8M→$322.5M

Current assets grew 20.4% — improving short-term liquidity or inventory/receivables build.

Revenue
P&L
+15.4%
$174.7M→$201.6M

Revenue growing 15.4% — solid top-line momentum, watch margins for quality of growth.

Gross Profit
P&L
+15.3%
$347.5M→$400.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Liabilities
Balance Sheet
+11%
$73.4M→$81.5M

Current liabilities rose 11% — increased short-term obligations, watch current ratio.

Accounts Receivable
Balance Sheet
+10.5%
$60.3M→$66.7M

Receivables grew 10.5% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-14
ADDED
BUSINESS Overview We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management.
Our pain management solutions are used by physicians to freeze nerves during cardiac, thoracic or amputation surgical procedures.
Recovery from these surgeries can be complicated and painful.
We sell our products to medical centers through our direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia and Canada.
During 2023, the American College of Cardiology (ACC), American Heart Association (AHA), American College of Clinical Pharmacy (ACCP) and HRS released Guidelines for Diagnosis and Management of Atrial Fibrillation, and upgraded LAAM to the highest recommendation of Class 1 and now include Hybrid AF Therapy as a Class 2 recommendation.
Additionally, our Le ft A trial A ppendage Exclusion for P rophylactic S troke Reduction (LeAAPS) IDE clinical trial is evaluating the safety and effectiveness of our AtriClip system in reducing stroke in cardiac surgery patients without a pre-existing Afib diagnosis.
Our Box Lesion and Left Atrial Appendage E X clusion Procedure for the Prevention of N ew O nset of A trial F ibrillation (BoxX-NoAF) IDE trial evaluates the impact of concomitant ablation using the EnCompass clamp and the AtriClip system in non-AF patients for the reduction of post-operative Afib (POAF) and clinical AF.
It is estimated that approximately 500,000 Afib patients are treated by catheter ablation every year in the United States, a number that is expected to see significant continued growth.
Beyond the Afib treatment opportunity, it is estimated that up to 50% of patients who undergo cardiac surgery who do not have diagnosed pre-operative Afib eventually develop POAF.
Patients with POAF tend to have worse acute and long-term clinical outcomes, including the risk of developing long-term clinical Afib.
REMOVED
BUSINESS Overview We are a leading innovator in treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management.
Our pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Recovery from cardiothoracic and thoracic surgery can be complicated and painful.
We sell our products to medical centers through our direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Canada and Australia.
In 2024, the European Society of Cardiology (ESC) released Guidelines for Management of Atrial Fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), in which they upgraded LAAM to the highest Class 1 recommendation.
It is estimated that approximately 500,000 Afib patients are treated by catheter ablation every year in the United States, a number that is expected to grow well over 10% annually.
Hospital recovery times can vary from two to fifteen days depending on the procedure, operative complications associated with the procedure, pain management protocol and other factors.
Further, applications for Cryo Nerve Block outside of thoracic surgery use are being studied by physician investigators and represent future possible growth opportunities.
In 2022, we launched the EnCompass clamp in the United States, following 510(k) clearance in 2021.
The AtriClip FLEX-Mini sets a new standard as the smallest profile for a surgical LAA device on the market and builds upon the proven technology and clinical benefits of our AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →